



CASE RESOLUTION WITHOUT HEARING

ADMC Program Rule 3312/Presence of a Controlled Medication Substance and/or its Metabolites or Markers

Covered Person: Jeffrey Englehart

Covered Horse: Graywing

On December 11, 2023, Jeffrey Englehart agreed to an Admission of Equine Controlled Medication Rule Violation(s) and Acceptance of Consequences pursuant to the Anti-Doping and Medication Control (ADMC) Program in connection with the above-referenced matter. This matter involved the presence of a Controlled Medication Substance and/or its Metabolites or Markers (ADMC Program Rule 3312) in a Post-Race Sample – Phenylbutazone (Class C). The Controlled Medication Substance was found to be present in a blood Sample collected from Graywing Post-Race after Race 3 at Finger Lakes Racetrack in Farmington, New York on July 17, 2023. This was his second Equine Controlled Substance Medication Violation with respect to a Class C substance.

As a result, the following Consequences were imposed against Mr. Englehart under the ADMC Program:

1. A period of Ineligibility of seven (7) days, commencing on December 13, 2023, and continuing through December 19, 2023 (ADMC Program Rule 3323);
2. Disqualification of the results of Graywing obtained in Race 3 at Finger Lakes Racetrack in Farmington, New York on July 17, 2023, and forfeiture of all purses and other compensation, prizes, trophies, points, and rankings and repayment or surrender (as applicable) to the Race Organizer pursuant to ADMC Program Rule 3321;
3. A fine of \$1,000 in accordance with ADMC Program Rule 3323;
4. The assignment of 1.5 Penalty Points pursuant to ADMC Program Rule 3328; and
5. Public Disclosure in accordance with ADMC Program Rule 3620.